Stocks
G1 Therapeutics Financial Statements (GTHX) |
||||||||||
| G1 Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2020 | 24.02.2021 | 23.02.2022 | 01.03.2023 | 28.02.2024 | 01.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 45.3 | 31.5 | 51.3 | 82.5 | 84.0 | |||
| Operating Income, bln rub | -129.0 | -96.5 | -142.5 | -136.2 | -39.5 | -22.8 | ||||
| EBITDA, bln rub | ? | -129.0 | -96.1 | -142.8 | -134.9 | -39.0 | -21.2 | |||
| Net profit, bln rub | ? | -122.1 | -99.3 | -148.4 | -147.6 | -48.0 | -30.6 | |||
| OCF, bln rub | ? | -99.6 | -83.7 | -132.1 | -128.6 | -38.3 | -18.2 | |||
| CAPEX, bln rub | ? | 2.72 | 0.000 | 0.000 | 0.506 | 0.000 | 0.000 | |||
| FCF, bln rub | ? | -102.3 | -83.7 | -132.1 | -129.1 | -38.3 | -18.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 129.0 | 141.8 | 171.9 | 183.7 | 114.8 | 103.1 | ||||
| Cost of production, bln rub | 0.356 | 0.000 | 2.02 | 3.75 | 7.20 | 6.82 | ||||
| R&D, bln rub | 89.0 | 73.3 | 76.2 | 83.3 | 43.7 | 35.5 | ||||
| Interest expenses, bln rub | 0.000 | 1.78 | 4.67 | 10.4 | 10.0 | 8.93 | ||||
| Assets, bln rub | 284.8 | 228.6 | 254.1 | 188.0 | 121.5 | 102.0 | ||||
| Net Assets, bln rub | ? | -336.9 | -436.1 | -584.5 | 68.7 | 35.4 | 27.7 | |||
| Debt, bln rub | 10.2 | 27.8 | 83.1 | 83.8 | 57.2 | 47.1 | ||||
| Cash, bln rub | 269.2 | 207.3 | 221.2 | 145.1 | 82.2 | 65.2 | ||||
| Net debt, bln rub | -259.0 | -179.5 | -138.1 | -61.3 | -25.0 | -18.2 | ||||
| Ordinary share price, rub | 26.4 | 18.0 | 10.2 | 5.43 | 3.05 | 1.61 | ||||
| Number of ordinary shares, mln | 37.5 | 37.9 | 41.9 | 43.6 | 51.7 | 52.2 | ||||
| Market cap, bln rub | 991 | 681 | 428 | 237 | 158 | 84 | ||||
| EV, bln rub | ? | 732 | 502 | 290 | 176 | 133 | 66 | |||
| Book value, bln rub | -337 | -436 | -584 | 69 | 35 | 28 | ||||
| EPS, rub | ? | -3.26 | -2.62 | -3.54 | -3.38 | -0.93 | -0.59 | |||
| FCF/share, rub | -2.73 | -2.21 | -3.15 | -2.96 | -0.74 | -0.35 | ||||
| BV/share, rub | -8.98 | -11.5 | -13.9 | 1.58 | 0.68 | 0.53 | ||||
| EBITDA margin, % | ? | -212.1% | -453.6% | -263.0% | -47.3% | -25.3% | ||||
| Net margin, % | ? | -219.2% | -471.3% | -287.6% | -58.1% | -36.4% | ||||
| FCF yield, % | ? | -10.3% | -12.3% | -30.8% | -54.5% | -24.3% | -21.6% | |||
| ROE, % | ? | 36.2% | 22.8% | 25.4% | -214.6% | -135.6% | -110.3% | |||
| ROA, % | ? | -42.9% | -43.4% | -58.4% | -78.5% | -39.5% | -30.0% | |||
| P/E | ? | -8.12 | -6.87 | -2.89 | -1.61 | -3.29 | -2.75 | |||
| P/FCF | -9.69 | -8.14 | -3.24 | -1.83 | -4.12 | -4.62 | ||||
| P/S | ? | 15.0 | 13.6 | 4.62 | 1.91 | 1.00 | ||||
| P/BV | ? | -2.94 | -1.56 | -0.73 | 3.45 | 4.46 | 3.03 | |||
| EV/EBITDA | ? | -5.67 | -5.22 | -2.03 | -1.30 | -3.40 | -3.10 | |||
| Debt/EBITDA | 2.01 | 1.87 | 0.97 | 0.45 | 0.64 | 0.85 | ||||
| R&D/CAPEX, % | 3 277% | 16 466% | ||||||||
| CAPEX/Revenue, % | 0.00% | 0.00% | 0.99% | 0.00% | 0 | |||||
| G1 Therapeutics shareholders | ||||||||||
